Article in The Globe, p.B10, April 08 on CXR
says,in part, that CXR "eyes more acquisitions," and CEO says that another TKO is likely in QIII. Also says "consolidation sweeping through the pharma indistry ("something like that")"
Do I hear us being labelled "Son of Valeant?" Rich, too rich.